[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sensus Healthcare Inc (SRTS)

Sensus Healthcare Inc (SRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract

Sensus Healthcare, Inc. (Nasdaq: SRTS) , a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological...

SRTS : 4.04 (+1.25%)
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base

Proprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and clinical utility ...

SRTS : 4.04 (+1.25%)
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology

New financing program provides a “one-stop” pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives Supports...

SRTS : 4.04 (+1.25%)
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer

2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 Company enters...

SRTS : 4.04 (+1.25%)
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological...

SRTS : 4.04 (+1.25%)
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco

Sensus Healthcare, Inc. (Nasdaq: SRTS) , a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological...

SRTS : 4.04 (+1.25%)
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

Sensus Healthcare, Inc. (Nasdaq: SRTS) , a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological...

SRTS : 4.04 (+1.25%)
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

New responsibilities recognize Mr. Sardano’s significant accomplishments in securing CPT ® codes for office-based SRT and the growing commercial opportunity the Company now faces...

SRTS : 4.04 (+1.25%)
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence

SRTS : 4.04 (+1.25%)
Sensus Healthcare Reports Third Quarter 2025 Financial Results

Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million ...

SRTS : 4.04 (+1.25%)

Barchart Exclusives

This Dividend Stock Keeps Hitting It Out of the Park: Should You Buy?
Citigroup's financial performance has been impressive over the last couple of years as its transformation under CEO Jane Fraser is bearing fruit. Is the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.